<DOC>
	<DOCNO>NCT00349531</DOCNO>
	<brief_summary>The primary objective study investigate effect RLS symptom sleep disturbance pramipexole ( Mirapexin ) 0.125 mg/day 0.75 mg/day per o 12 week , compare placebo , treatment patient idiopathic Restless Legs Syndrome</brief_summary>
	<brief_title>A Phase IV Trial With Pramipexole Investigate Effects RLS Symptoms Sleep Disturbance Patients With RLS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Dyssomnias</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Written inform consent consistent ICHGCP local IRB/IEC requirement obtain prior study procedure perform ability willingness comply study treatment regimen attend study assessment . 2 . Male female outpatient age 1880 year . 3 . Diagnosis idiopathic RLS accord clinical RLS criterion IRLSSG [ P0303355 ] . All four criterion must present fulfil diagnosis RLS : An urge move leg , usually accompany cause uncomfortable unpleasant sensation leg . ( Sometimes urge move present without uncomfortable sensation sometimes arm body part involve addition leg ) The urge move unpleasant sensation begin worsen period rest inactivity lie sit The urge move unpleasant sensation partially totally relieved movement , walk stretch , least long activity continue The urge move unpleasant sensation worse even night day occur even night . ( When symptom severe , worsen night may noticeable must previously present ) . 4 . RLS symptoms present least 2 3 day per week last 3 month prior baseline ( Visit 2 ) . 5 . IRLS total score &gt; 15 baseline ( Visit 2 ) . 1 . Women childbearing potential use trial adequate method contraception . 2 . Women childbearing potential negative pregnancy test screening . 3 . Breastfeeding woman . 4 . Concomitant previous pharmacologic therapy RLS : dopamine agonist levodopa ( within 14 day prior baseline ) , levodopa augmentation , unsuccessful prior treatment nonergot dopamine agonist . 5 . All treatment less 14 day concomitant treatment medication dietary supplement could significantly influence RLS symptom . 6 . Withdrawal symptom . 7 . Pramipexole nonresponders indication RLS . 8 . Patients know hypersensitivity pramipexole component investigational product placebo tablet . 9 . Diabetes mellitus require insulin therapy . 10 . Any following laboratory result screen : clinically significant abnormality laboratory parameter ; haemoglobin LLN . 11 . Clinically significant renal disease calculate creatinine clearance lower 30 mL/minute . 12 . Clinically significant hepatic disease GPT &gt; 2 time ULN . 13 . Serum ferritin &lt; 10 ng/mL . 14 . History of/or malignant melanoma . 15 . History of/or clinically significant vision abnormality . 16 . History of/or sleep disorder ( RLSrelated ) . 17 . History of/or major depressive disorder psychotic disorder , mental disorder present Axis I psychiatric disorder accord DSM IV require medical therapy . 18 . History of/or clinical sign suicidal behaviour , suicide ideation acute suicidal tendency accord investigator 's opinion . 19 . History of/or alcohol abuse drug addiction ( within 2 year ) . 20 . Patients shiftworkschedule otherwise unable follow regular sleepwake cycle . 21 . Participation investigational drug study within one month . 22 . Any clinically significant condition would interfere constitute health hazard patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>